{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:00:54Z","timestamp":1792267254319,"version":"4.4.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K22 CA201036"],"award-info":[{"award-number":["K22 CA201036"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA237643"],"award-info":[{"award-number":["R01 CA237643"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["NHLBI F31 HL151111-01"],"award-info":[{"award-number":["NHLBI F31 HL151111-01"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["R01 CA237643"],"award-info":[{"award-number":["R01 CA237643"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["IRG-85-001-25"],"award-info":[{"award-number":["IRG-85-001-25"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000043","name":"American Association for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000043","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["T32 5T32ES007266-30"],"award-info":[{"award-number":["T32 5T32ES007266-30"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20 GM121327-03"],"award-info":[{"award-number":["P20 GM121327-03"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015087","name":"Markey Cancer Center, University of Kentucky","doi-asserted-by":"publisher","award":["P30CA177558"],"award-info":[{"award-number":["P30CA177558"]}],"id":[{"id":"10.13039\/100015087","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.canlet.2021.10.010","type":"journal-article","created":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T12:13:31Z","timestamp":1634213611000},"page":"151-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["EZH2 inhibition confers PIK3CA-driven lung tumors enhanced sensitivity to PI3K inhibition"],"prefix":"10.1016","volume":"524","author":[{"given":"Fan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinpeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiulong","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanner J.","family":"DuCote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aria L.","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0854-5043","authenticated-orcid":false,"given":"Christine F.","family":"Brainson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5670","key":"10.1016\/j.canlet.2021.10.010_bib1","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1126\/science.1096502","article-title":"High frequency of mutations of the PIK3CA gene in human cancers","volume":"304","author":"Samuels","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.canlet.2021.10.010_bib2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/OTT.S89967","article-title":"PI3K inhibitors as new cancer therapeutics: implications for clinical trial design","volume":"9","author":"Massacesi","year":"2016","journal-title":"OncoTargets Ther."},{"issue":"9","key":"10.1016\/j.canlet.2021.10.010_bib3","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/JTO.0000000000000607","article-title":"Safety and efficacy of buparlisib (BKM120) in patients with PI3K pathway-activated non-small cell lung cancer: results from the phase II BASALT-1 study","volume":"10","author":"Vansteenkiste","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2021.10.010_bib4","first-page":"511","article-title":"Targeting the PI3K\/Akt\/mTOR pathway in non-small cell lung cancer (NSCLC)","volume":"11","author":"Tan","year":"2020"},{"issue":"10","key":"10.1016\/j.canlet.2021.10.010_bib5","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/nrm2763","article-title":"Mechanisms of Polycomb gene silencing: knowns and unknowns","volume":"10","author":"Simon","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1\u20132","key":"10.1016\/j.canlet.2021.10.010_bib6","first-page":"21","article-title":"Roles of the EZH2 histone methyltransferase in cancer epigenetics","volume":"647","author":"Simon","year":"2008","journal-title":"Mutat. Res. Fund Mol. Mech. Mutagen"},{"issue":"11","key":"10.1016\/j.canlet.2021.10.010_bib7","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/nrc2736","article-title":"Polycomb group proteins: navigators of lineage pathways led astray in cancer","volume":"9","author":"Bracken","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.canlet.2021.10.010_bib8","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40265-020-01288-x","article-title":"Tazemetostat: first approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"issue":"17","key":"10.1016\/j.canlet.2021.10.010_bib9","doi-asserted-by":"crossref","first-page":"6913","DOI":"10.1158\/0008-5472.CAN-07-5084","article-title":"PIK3CA mutations and copy number gains in human lung cancers","volume":"68","author":"Yamamoto","year":"2008","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.canlet.2021.10.010_bib10","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/sj.bjc.6601894","article-title":"The COSMIC (catalogue of somatic mutations in cancer) database and website","volume":"91","author":"Bamford","year":"2004","journal-title":"Br. J. Cancer"},{"issue":"7391","key":"10.1016\/j.canlet.2021.10.010_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/nature11003","article-title":"The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2021.10.010_bib12","doi-asserted-by":"crossref","first-page":"e12703","DOI":"10.7554\/eLife.12703","article-title":"Mouse models of human PIK3CA-related brain overgrowth have acutely treatable epilepsy","volume":"4","author":"Roy","year":"2015","journal-title":"eLife"},{"issue":"7409","key":"10.1016\/j.canlet.2021.10.010_bib13","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature11213","article-title":"Novel mutations target distinct subgroups of medulloblastoma","volume":"488","author":"Robinson","year":"2012","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.canlet.2021.10.010_bib14","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1101\/gad.14.8.994","article-title":"Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum","volume":"14","author":"Marino","year":"2000","journal-title":"Genes Dev."},{"issue":"5","key":"10.1016\/j.canlet.2021.10.010_bib15","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ccr.2014.03.033","article-title":"Loss of Lkb1 and pten leads to lung squamous cell carcinoma with elevated PD-L1 expression","volume":"25","author":"Xu","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2021.10.010_bib16","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/embj.201386082","article-title":"Tumor-propagating cells and Yap\/Taz activity contribute to lung tumor progression and metastasis","volume":"33","author":"Lau","year":"2014","journal-title":"EMBO J."},{"issue":"19","key":"10.1016\/j.canlet.2021.10.010_bib17","doi-asserted-by":"crossref","first-page":"7922","DOI":"10.1073\/pnas.1303800110","article-title":"Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2","volume":"110","author":"Knutson","year":"2012","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"issue":"11","key":"10.1016\/j.canlet.2021.10.010_bib18","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1158\/1535-7163.MCT-12-0993-T","article-title":"BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110\u03b1 and p110\u03b4 activities in tumor cell lines and xenograft models","volume":"12","author":"Liu","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.canlet.2021.10.010_bib19","doi-asserted-by":"crossref","first-page":"8867","DOI":"10.1038\/s41598-020-65637-2","article-title":"Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts","volume":"10","author":"Fang","year":"2020","journal-title":"Sci. Rep."},{"issue":"W1","key":"10.1016\/j.canlet.2021.10.010_bib20","doi-asserted-by":"crossref","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","article-title":"SynergyFinder 2.0: visual analytics of multi-drug combination synergies","volume":"48","author":"Ianevski","year":"2020","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.canlet.2021.10.010_bib21","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/toxsci\/kfr029","article-title":"Reversal and prevention of arsenic-induced human bronchial epithelial cell malignant transformation by microRNA-200b","volume":"121","author":"Wang","year":"2011","journal-title":"Toxicol. Sci."},{"issue":"3","key":"10.1016\/j.canlet.2021.10.010_bib22","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.cell.2013.12.039","article-title":"Lung stem cell differentiation in mice directed by endothelial cells via a BMP4-NFATc1-thrombospondin-1 axis","volume":"156","author":"Lee","year":"2014","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.canlet.2021.10.010_bib23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.stem.2010.12.007","article-title":"Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate","volume":"8","author":"Proia","year":"2011","journal-title":"Cell Stem Cell"},{"issue":"51","key":"10.1016\/j.canlet.2021.10.010_bib24","doi-asserted-by":"crossref","first-page":"18443","DOI":"10.1073\/pnas.0508988102","article-title":"The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells","volume":"102","author":"Zhao","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"15","key":"10.1016\/j.canlet.2021.10.010_bib25","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","article-title":"Trimmomatic: a flexible trimmer for Illumina sequence data","volume":"30","author":"Bolger","year":"2014","journal-title":"Bioinformatics"},{"issue":"1","key":"10.1016\/j.canlet.2021.10.010_bib26","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/1471-2105-12-323","article-title":"RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome","volume":"12","author":"Li","year":"2011","journal-title":"BMC Bioinf."},{"issue":"1","key":"10.1016\/j.canlet.2021.10.010_bib27","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"issue":"43","key":"10.1016\/j.canlet.2021.10.010_bib28","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"issue":"5","key":"10.1016\/j.canlet.2021.10.010_bib29","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"issue":"269","key":"10.1016\/j.canlet.2021.10.010_bib30","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"issue":"7427","key":"10.1016\/j.canlet.2021.10.010_bib31","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature11606","article-title":"EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations","volume":"492","author":"McCabe","year":"2012","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.canlet.2021.10.010_bib32","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ijc.2910610210","article-title":"SV40-induced immortalization and ras-transformation of human bronchial epithelial cells","volume":"61","author":"Reddel","year":"1995","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2021.10.010_bib33","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.canlet.2019.03.047","article-title":"Mutant p53(R175H) promotes cancer initiation in the pancreas by stabilizing HSP70","volume":"453","author":"Polireddy","year":"2019","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.canlet.2021.10.010_bib34","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.bbrc.2006.08.120","article-title":"Akt phosphorylation is essential for nuclear translocation and retention in NGF-stimulated PC12 cells","volume":"349","author":"Xuan Nguyen","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"8","key":"10.1016\/j.canlet.2021.10.010_bib35","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1101\/gad.1897010","article-title":"Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer","volume":"24","author":"Oliver","year":"2010","journal-title":"Genes & Development"},{"issue":"1","key":"10.1016\/j.canlet.2021.10.010_bib36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccell.2015.12.006","article-title":"Polycomb repressive complex 2 is a barrier to KRAS-driven inflammation and epithelial-mesenchymal transition in non-small-cell lung cancer","volume":"29","author":"Serresi","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2021.10.010_bib37","article-title":"Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2","volume":"8","author":"Zhang","year":"2017","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.canlet.2021.10.010_bib38","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.cell.2013.12.039","article-title":"Lung stem cell differentiation in mice directed by endothelial cells via a BMP4-NFATc1-thrombospondin-1 Axis","volume":"156","author":"Lee","year":"2014","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.canlet.2021.10.010_bib39","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.stem.2020.07.022","article-title":"Organoids model transcriptional Hallmarks of oncogenic KRAS activation in lung epithelial progenitor cells","volume":"27","author":"Dost","year":"2020","journal-title":"Cell Stem Cell"},{"issue":"5","key":"10.1016\/j.canlet.2021.10.010_bib40","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2021.10.010_bib41","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nm.3799","article-title":"Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers","volume":"21","author":"Bitler","year":"2015","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.canlet.2021.10.010_bib42","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/nm.1890","article-title":"Effective use of PI3K and MEK inhibitors to treat mutant K-ras G12D and PIK3CA H1047R murine lung cancers","volume":"14","author":"Engelman","year":"2008","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.canlet.2021.10.010_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2013.38","article-title":"Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R","volume":"2","author":"Meyer","year":"2013","journal-title":"Oncogenesis"},{"issue":"1","key":"10.1016\/j.canlet.2021.10.010_bib44","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1038\/s41467-017-02002-4","article-title":"Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling","volume":"8","author":"Berenjeno","year":"2017","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.canlet.2021.10.010_bib45","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1158\/1078-0432.CCR-18-1593","article-title":"Low-pass whole-genome sequencing of circulating cell-free DNA demonstrates dynamic changes in genomic copy number in a squamous lung cancer clinical cohort","volume":"25","author":"Chen","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2021.10.010_bib46","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10637-016-0382-3","article-title":"Phase Ia\/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer","volume":"35","author":"Yamamoto","year":"2017","journal-title":"Invest. N. Drugs"},{"issue":"3","key":"10.1016\/j.canlet.2021.10.010_bib47","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/1759-7714.13328","article-title":"Targeting the PI3K\/Akt\/mTOR pathway in non-small cell lung cancer (NSCLC)","volume":"11","author":"Tan","year":"2020","journal-title":"Thorac Cancer"},{"issue":"3","key":"10.1016\/j.canlet.2021.10.010_bib48","doi-asserted-by":"crossref","first-page":"e963447","DOI":"10.4161\/23723548.2014.963447","article-title":"Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment","volume":"1","author":"Castel","year":"2014","journal-title":"Mol Cell Oncol"},{"issue":"3","key":"10.1016\/j.canlet.2021.10.010_bib49","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jtho.2015.10.025","article-title":"HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers","volume":"11","author":"Li","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canlet.2021.10.010_bib50","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.bcp.2018.12.010","article-title":"Lung cancer stem cells: origin, features, maintenance mechanisms and therapeutic targeting","volume":"160","author":"Heng","year":"2019","journal-title":"Biochem. Pharmacol."},{"issue":"17","key":"10.1016\/j.canlet.2021.10.010_bib51","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1242\/dev.137075","article-title":"Proliferation, survival and metabolism: the role of PI3K\/AKT\/mTOR signalling in pluripotency and cell fate determination","volume":"143","author":"Yu","year":"2016","journal-title":"Development"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521005206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521005206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:46:02Z","timestamp":1778507162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383521005206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":51,"alternative-id":["S0304383521005206"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2021.10.010","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EZH2 inhibition confers PIK3CA-driven lung tumors enhanced sensitivity to PI3K inhibition","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2021.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}